Hugh O’Neill is executive vice president and president of autoimmune and rare diseases at Mallinckrodt Pharmaceuticals. He has executive responsibility and directly manages all commercialization efforts and broad market access activites for this portfolio within the company's Specialty Brands segment. Mr. O’Neill is a member of Mallinckrodt’s executive committee. Mr. O’Neill has more than 20 years of experience in new product planning and execution, business development, strategic planning, marketing, general management, finance and market access in the pharmaceutical industry. Before joining Mallinckrodt, Mr. O’Neill held various commercial leadership positions at Sanofi, including vice president of commercial excellence, general manager, president of Sanofi Canada, and vice president of market access and business development. He has also worked at Pharmacia, Novartis and Sandoz, crafting commercial strategies and operational plans across all facets of various organizations — including commercial coordination within research and development, new product launches, field force leadership, strategic marketing, business development, and market access.  

Mr. O’Neill has more than 20 years of experience in new product planning and execution, business development, strategic planning, marketing, general management, finance and market access in the pharmaceutical industry.